{"success":true,"data":{"pressRelease":{"id":"37964","rtpr_id":"nGNX4kmbzS","ticker":"QNCX","exchange":"NASDAQ","all_tickers":["QNCX"],"title":"Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD","author":"Globe Newswire","published_at":"2026-05-18T13:26:19.143Z","article_body":"* Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD\npatients with refractory PH demonstrated clinically meaningful improvement in\nmultiple assessments of lung function, including improvement in 6MWD of 67.4\nmeters and PVR reduction of 33.9% at 24 weeks\n* Phase 2b trial in PH-ILD to initiate in mid-2026, with topline data\nanticipated in the first quarter of 2028\n* Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET\nSOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince\nTherapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001,\nan inhaled formulation of rapamycin (mTOR inhibitor), in patients with\npulmonary arterial hypertension (PAH) and pulmonary hypertension associated\nwith interstitial lung disease (PH-ILD), presented at the American Thoracic\nSociety (ATS) conference in Orlando. The Company recently acquired LAM-001\nthrough its previously announced acquisition of Orphai Therapeutics, Inc., a\nclinical-stage biotechnology company developing LAM-001 to treat rare\npulmonary diseases\n\nThe Phase 2a study was a 24-week, open-label trial conducted across four\nclinical sites evaluating LAM-001 as an add-on therapy to standard of care\n(SOC) in 10 adult patients with PAH and PH-ILD who remained symptomatic\ndespite background therapy. Primary endpoints included change from baseline in\npeak oxygen uptake (VO2 max) at Week 24, safety and tolerability. Secondary\nendpoints included pulmonary vascular resistance (PVR), six-minute walk\ndistance (6MWD) and change in functional class, with change in N-terminal\npro-B-type natriuretic peptide (NT-proBNP) assessed as an exploratory\nendpoint.\n\nLAM-001 Demonstrated Clinically Meaningful Improvements Across Key Measures of\nPulmonary Vascular Disease\n\nTreatment with LAM-001 was associated with improvement or stabilization from\nbaseline across multiple clinically relevant measures, including 6MWD, PVR,\nNT-proBNP and forced vital capacity (FVC), supporting potential benefit across\nexercise capacity, pulmonary hemodynamics, cardiac stress and lung function.\n\nImprovements in 6MWD, a clinically meaningful endpoint commonly used in\npulmonary hypertension clinical trials and regulatory submissions, were\nobserved alongside favorable changes in hemodynamic and biomarker measures.\nAll evaluable patients also transitioned from Functional Class III to\nFunctional Class II by Week 24. In addition, two patients transitioned to\nFunctional Class I at 16- and 52-week evaluations.\n\nLAM-001 was generally well tolerated in patients receiving background\nstandard-of-care therapy. A total of 6 patients were evaluable at the 24-week\nendpoint, of which 4 were PH-ILD patients. All 4 PH-ILD patients were\nreceiving stable doses of treprostinil therapy before and throughout the\nstudy.\n\nLAM-001 Phase 2a PH Efficacy\n\n                         Evaluable Population N=6  PH-ILD Subgroup N=4  \n Δ6MWD (m)               +81.3                     +67.4                \n Δ VO2 Max (Predicted)   +5.4%                     +6.7%                \n % Δ PVR (exercise)      -25.5%                    35.3%                \n % Δ PVR (supine)        28.1%                     -33.9%               \n % Δ NT-proBNP           -29.0%                    -28.8%               \n Δ FVC (% Predicted)     +4.8%                     +1.8%                \n\n(6MWD = six-minute walk distance; VO2 Max = peak oxygen uptake; PVR =\npulmonary vascular resistance; NT-proBNP = N-terminal pro-B-type natriuretic\npeptide; FVC = forced vital capacity; % predicted compares a patient’s value\nto expected normal values based on demographic characteristics.)\n\n“Patients with PH-ILD continue to face substantial limitations in daily\nfunctioning and a high risk of clinical deterioration despite currently\navailable therapies,” said Aaron B. Waxman, M.D., Ph.D., Director of the\nPulmonary Vascular Disease Program at Brigham and Women’s Hospital and\nAssociate Professor of Medicine at Harvard Medical School. “What is\nparticularly notable in these early data is the consistency of improvement\nobserved across several important markers of disease burden, including\nexercise capacity, pulmonary vascular resistance, cardiac stress biomarkers\nand lung function. Improvements in measures such as 6MWD and PVR are\nespecially encouraging given their clinical relevance in pulmonary\nhypertension and may suggest broader effects on cardiopulmonary physiology.\nThese findings are encouraging for patients and the broader pulmonary\nhypertension community and support continued development of LAM-001 in PH-ILD,\nwhere meaningful therapeutic advances remain urgently needed.”\n\nAbout LAM-001\n\nLAM-001 is a proprietary, investigational, once-daily inhaled formulation of\nsirolimus, also known as rapamycin. LAM-001’s potential as a\ndisease-modifying agent in pulmonary hypertension stems from its ability to\ninhibit mTOR-mediated pulmonary arterial smooth muscle cell proliferation. The\nmTOR pathway has been shown to be activated in the pulmonary arterial smooth\nmuscle cells of patients with pulmonary hypertension, and mTOR inhibition with\nrapamycin has been shown to reverse smooth muscle cell hyperproliferation and\nattenuate pulmonary vascular remodeling and cardiopulmonary dysfunction in\nmultiple nonclinical models. Additionally, mTOR signaling promotes fibroblast\nactivation, myofibroblast differentiation, and extracellular matrix deposition\nin injured or inflamed lung tissue, and mTOR inhibition has been shown to\nexert direct anti-fibrotic activity, reducing collagen accumulation,\nsuppressing profibrotic cytokine signaling, and attenuating parenchymal\nfibrosis. These effects are particularly relevant in pulmonary hypertension\nassociated with interstitial lung disease (PH-ILD), where vascular remodeling\nand progressive fibrosis evolve in parallel and amplify pulmonary vascular\nload. LAM-001 is designed to enhance pulmonary delivery and reduce systemic\nexposure, offering a promising potential disease-modifying therapy for\npulmonary disease.  \n\nLAM-001 is currently being studied in multiple indications including pulmonary\nhypertension associated with interstitial lung disease (PH-ILD), a serious and\nprogressive condition affecting an estimated ~86K patients in the U.S. and\n~120K in Europe. Based on compelling Phase 2a data presented at the American\nThoracic Society (ATS) in May 2026, the company is advancing LAM-001 into a\nPhase 2b trial in PH-ILD, with initiation planned for mid-2026 and data\nanticipated in the first quarter of 2028. LAM-001 is also being evaluated in a\nPhase 2 study in bronchiolitis obliterans syndrome (BOS), a serious\ncomplication following lung transplantation affecting an estimated ~17K\npatients in the U.S. and ~11K in Europe, with data anticipated in the first\nquarter of 2027. In late 2026, the company also plans to initiate a Phase 2\nstudy of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a\nsevere complication of sarcoidosis with no approved therapy affecting an\nestimated ~60K patients in the U.S. and Europe.\n\nPhase 2a Study Design\n\nThe Phase 2a study (NCT05798923\n(https://www.globenewswire.com/Tracker?data=AkU2Lb3AG3ZNgvcMyXvEjuwaXFehIpjJZia1-1HPOhE6x-e3ZlSjoZ73ff-3y2z8XDo1zQYWu7ajVJSEAasMZzCzqooytzBoSlzbPDG7smvE4qTGRpxGk54bsLaSrWbCI5rYwfdAUUQ8yD1EcO2tRgMcdD4S2_KcIsP8b-2g8N8=))\nwas a 10-patient, multicenter, open-label trial evaluating the safety,\ntolerability and efficacy of LAM-001 as an add-on therapy to standard of care\n(SOC) in adult patients with pulmonary arterial hypertension (PAH) and\npulmonary hypertension associated with interstitial lung disease (PH-ILD) who\nremained symptomatic despite background therapy. The 24-week study was\nconducted across four clinical sites in the United States. Primary endpoints\nincluded change in peak oxygen uptake (VO2 max) from baseline to Week 24 as\nwell as safety and tolerability. Secondary endpoints included change in\npulmonary vascular resistance (PVR), six-minute walk distance (6MWD) and\nfunctional class assessments. Exploratory endpoints included change in\nN-terminal pro-B-type natriuretic peptide (NT-proBNP) and forced vital\ncapacity (FVC).\n\nWebcast Details\n\n Monday, May 18th @ 10:00 a.m. ET                                                                                                                                                         \n                                                                                                                                                                                          \n Investors:                  1-877-407-0784                                                                                                                                               \n                                                                                                                                                                                          \n International Investors:    1-201-689-8560                                                                                                                                               \n                                                                                                                                                                                          \n Conference ID:              13760654                                                                                                                                                     \n                                                                                                                                                                                          \n Webcast:                    Click Here (https://viavid.webcasts.com/starthere.jsp?ei=1763509&tp_key=187466c723)                                                                          \n                                                                                                                                                                                          \n Call me™:                   Click Here (https://callme.viavid.com/viavid/?callme=true&passcode=13760654&h=true&info=Company-email&r=true&B=6)for instant telephone access to the event.  \n                                                                                                                                                                                          \n\nA replay of the webcast presentation will be temporarily archived on the\nInvestors section of Quince’s website following the presentation.\n\nAbout Quince Therapeutics, Inc.\n\nQuince Therapeutics, Inc. is committed to transforming the lives of patients\nfacing serious, underserved diseases by developing disease-modifying therapies\nto treat their conditions. The company is currently developing LAM-001 for the\ntreatment of pulmonary hypertension associated with interstitial lung disease\n(PH-ILD), bronchiolitis obliterans syndrome (BOS), and sarcoidosis associated\npulmonary hypertension (SAPH).  A Phase 2a study in PH patients has been\ncompleted, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b\nstudy in PH-ILD is anticipated to begin in mid-2026, and a Phase 2 study in\nSAPH is anticipated to begin in late-2026.  By pioneering innovative\napproaches, the company aims to offer new hope and improved quality of life to\npatients worldwide.\n\nForward Looking Statements\n\nStatements in this news release contain “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995 as\ncontained in Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended, which are\nsubject to the “safe harbor” created by those sections. All statements,\nother than statements of historical facts, may be forward-looking statements.\nForward-looking statements contained in this news release may be identified by\nthe use of words such as “believe,” “may,” “should,” “expect,”\n“anticipate,” “plan,” “believe,” “estimated,” “potential,”\n“intend,” “will,” “can,” “seek,” or other similar words.\nExamples of forward-looking statements include, among others, statements\nrelating to the design and potential benefits of LAM-001, including as a\ndisease-modifying therapy for pulmonary disease; anticipated regulatory and\ndevelopment processes and timelines, including the expected timing to initiate\nthe planned Phase 2b trial of LAM-001 in PH-ILD and the planned Phase 2 trial\nof LAM-001 in SAPH, the expected timing for data readouts from the ongoing\nPhase 2 trial of LAM-001 in BOS and the planned Phase 2b trial of LAM-001 in\nPH-ILD; the Phase 2a data of LAM-001 in PAH and PH-ILD supporting continued\ndevelopment of LAM-001 in PH-ILD and the potential benefit across exercise\ncapacity, pulmonary hemodynamics, cardiac stress and lung function; observed\nimprovements in 6MWD and PVR in the Phase 2a trial potentially suggesting\nbroader effects on cardiopulmonary physiology; the estimated patient\npopulations in the U.S. and Europe for PH-ILD, BOS and SAPH; and the potential\nadvantages of mTOR inhibitors in PH-ILD. Forward-looking statements are based\non Quince’s current expectations and are subject to inherent uncertainties,\nrisks, and assumptions that are difficult to predict and could cause actual\nresults to differ materially from what the company expects. Further, certain\nforward-looking statements are based on assumptions as to future events that\nmay not prove to be accurate. Factors that could cause actual results to\ndiffer include, but are not limited to, clinical results may not be indicative\nof results that may be observed in the future, including in larger\npopulations; potential safety and other complications related to LAM-001; the\nability to obtain and maintain regulatory approval; competition in the\ncompany’s industry; the scope, progress and expansion of developing LAM-001;\nthe size and growth of the market(s) therefor and the rate and degree of\nmarket acceptance thereof vis-à-vis alternative therapies; the company’s\nability to attract or retain key management, members of the board of directors\nand other personnel; the impacts of general macroeconomic and geopolitical\nconditions on the company’s business and financial position; and other risks\nand uncertainties described in the section titled “Risk Factors” in the\ncompany’s Annual Report on Form 10-K filed with the Securities and\nExchange Commission (SEC) on April 10, 2026 and other reports as filed with\nthe SEC. Forward-looking statements contained in this news release are made as\nof this date, and Quince undertakes no duty to update such information except\nas required under applicable law.\n\nContacts\n\nCorey Davis, Ph.D.\nLifeSci Advisors, LLC\ncdavis@lifesciadvisors.com  \n212-915-2577\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2d9c6375-d986-407f-affb-1308a5bb5bf6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4kmbzS","title":"Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD","author":"Globe Newswire","ticker":"QNCX","created":"2026-05-18T13:26:19.143Z","tickers":["QNCX"],"exchange":"NASDAQ","article_body":"* Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD\npatients with refractory PH demonstrated clinically meaningful improvement in\nmultiple assessments of lung function, including improvement in 6MWD of 67.4\nmeters and PVR reduction of 33.9% at 24 weeks\n* Phase 2b trial in PH-ILD to initiate in mid-2026, with topline data\nanticipated in the first quarter of 2028\n* Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET\nSOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince\nTherapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001,\nan inhaled formulation of rapamycin (mTOR inhibitor), in patients with\npulmonary arterial hypertension (PAH) and pulmonary hypertension associated\nwith interstitial lung disease (PH-ILD), presented at the American Thoracic\nSociety (ATS) conference in Orlando. The Company recently acquired LAM-001\nthrough its previously announced acquisition of Orphai Therapeutics, Inc., a\nclinical-stage biotechnology company developing LAM-001 to treat rare\npulmonary diseases\n\nThe Phase 2a study was a 24-week, open-label trial conducted across four\nclinical sites evaluating LAM-001 as an add-on therapy to standard of care\n(SOC) in 10 adult patients with PAH and PH-ILD who remained symptomatic\ndespite background therapy. Primary endpoints included change from baseline in\npeak oxygen uptake (VO2 max) at Week 24, safety and tolerability. Secondary\nendpoints included pulmonary vascular resistance (PVR), six-minute walk\ndistance (6MWD) and change in functional class, with change in N-terminal\npro-B-type natriuretic peptide (NT-proBNP) assessed as an exploratory\nendpoint.\n\nLAM-001 Demonstrated Clinically Meaningful Improvements Across Key Measures of\nPulmonary Vascular Disease\n\nTreatment with LAM-001 was associated with improvement or stabilization from\nbaseline across multiple clinically relevant measures, including 6MWD, PVR,\nNT-proBNP and forced vital capacity (FVC), supporting potential benefit across\nexercise capacity, pulmonary hemodynamics, cardiac stress and lung function.\n\nImprovements in 6MWD, a clinically meaningful endpoint commonly used in\npulmonary hypertension clinical trials and regulatory submissions, were\nobserved alongside favorable changes in hemodynamic and biomarker measures.\nAll evaluable patients also transitioned from Functional Class III to\nFunctional Class II by Week 24. In addition, two patients transitioned to\nFunctional Class I at 16- and 52-week evaluations.\n\nLAM-001 was generally well tolerated in patients receiving background\nstandard-of-care therapy. A total of 6 patients were evaluable at the 24-week\nendpoint, of which 4 were PH-ILD patients. All 4 PH-ILD patients were\nreceiving stable doses of treprostinil therapy before and throughout the\nstudy.\n\nLAM-001 Phase 2a PH Efficacy\n\n                         Evaluable Population N=6  PH-ILD Subgroup N=4  \n Δ6MWD (m)               +81.3                     +67.4                \n Δ VO2 Max (Predicted)   +5.4%                     +6.7%                \n % Δ PVR (exercise)      -25.5%                    35.3%                \n % Δ PVR (supine)        28.1%                     -33.9%               \n % Δ NT-proBNP           -29.0%                    -28.8%               \n Δ FVC (% Predicted)     +4.8%                     +1.8%                \n\n(6MWD = six-minute walk distance; VO2 Max = peak oxygen uptake; PVR =\npulmonary vascular resistance; NT-proBNP = N-terminal pro-B-type natriuretic\npeptide; FVC = forced vital capacity; % predicted compares a patient’s value\nto expected normal values based on demographic characteristics.)\n\n“Patients with PH-ILD continue to face substantial limitations in daily\nfunctioning and a high risk of clinical deterioration despite currently\navailable therapies,” said Aaron B. Waxman, M.D., Ph.D., Director of the\nPulmonary Vascular Disease Program at Brigham and Women’s Hospital and\nAssociate Professor of Medicine at Harvard Medical School. “What is\nparticularly notable in these early data is the consistency of improvement\nobserved across several important markers of disease burden, including\nexercise capacity, pulmonary vascular resistance, cardiac stress biomarkers\nand lung function. Improvements in measures such as 6MWD and PVR are\nespecially encouraging given their clinical relevance in pulmonary\nhypertension and may suggest broader effects on cardiopulmonary physiology.\nThese findings are encouraging for patients and the broader pulmonary\nhypertension community and support continued development of LAM-001 in PH-ILD,\nwhere meaningful therapeutic advances remain urgently needed.”\n\nAbout LAM-001\n\nLAM-001 is a proprietary, investigational, once-daily inhaled formulation of\nsirolimus, also known as rapamycin. LAM-001’s potential as a\ndisease-modifying agent in pulmonary hypertension stems from its ability to\ninhibit mTOR-mediated pulmonary arterial smooth muscle cell proliferation. The\nmTOR pathway has been shown to be activated in the pulmonary arterial smooth\nmuscle cells of patients with pulmonary hypertension, and mTOR inhibition with\nrapamycin has been shown to reverse smooth muscle cell hyperproliferation and\nattenuate pulmonary vascular remodeling and cardiopulmonary dysfunction in\nmultiple nonclinical models. Additionally, mTOR signaling promotes fibroblast\nactivation, myofibroblast differentiation, and extracellular matrix deposition\nin injured or inflamed lung tissue, and mTOR inhibition has been shown to\nexert direct anti-fibrotic activity, reducing collagen accumulation,\nsuppressing profibrotic cytokine signaling, and attenuating parenchymal\nfibrosis. These effects are particularly relevant in pulmonary hypertension\nassociated with interstitial lung disease (PH-ILD), where vascular remodeling\nand progressive fibrosis evolve in parallel and amplify pulmonary vascular\nload. LAM-001 is designed to enhance pulmonary delivery and reduce systemic\nexposure, offering a promising potential disease-modifying therapy for\npulmonary disease.  \n\nLAM-001 is currently being studied in multiple indications including pulmonary\nhypertension associated with interstitial lung disease (PH-ILD), a serious and\nprogressive condition affecting an estimated ~86K patients in the U.S. and\n~120K in Europe. Based on compelling Phase 2a data presented at the American\nThoracic Society (ATS) in May 2026, the company is advancing LAM-001 into a\nPhase 2b trial in PH-ILD, with initiation planned for mid-2026 and data\nanticipated in the first quarter of 2028. LAM-001 is also being evaluated in a\nPhase 2 study in bronchiolitis obliterans syndrome (BOS), a serious\ncomplication following lung transplantation affecting an estimated ~17K\npatients in the U.S. and ~11K in Europe, with data anticipated in the first\nquarter of 2027. In late 2026, the company also plans to initiate a Phase 2\nstudy of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a\nsevere complication of sarcoidosis with no approved therapy affecting an\nestimated ~60K patients in the U.S. and Europe.\n\nPhase 2a Study Design\n\nThe Phase 2a study (NCT05798923\n(https://www.globenewswire.com/Tracker?data=AkU2Lb3AG3ZNgvcMyXvEjuwaXFehIpjJZia1-1HPOhE6x-e3ZlSjoZ73ff-3y2z8XDo1zQYWu7ajVJSEAasMZzCzqooytzBoSlzbPDG7smvE4qTGRpxGk54bsLaSrWbCI5rYwfdAUUQ8yD1EcO2tRgMcdD4S2_KcIsP8b-2g8N8=))\nwas a 10-patient, multicenter, open-label trial evaluating the safety,\ntolerability and efficacy of LAM-001 as an add-on therapy to standard of care\n(SOC) in adult patients with pulmonary arterial hypertension (PAH) and\npulmonary hypertension associated with interstitial lung disease (PH-ILD) who\nremained symptomatic despite background therapy. The 24-week study was\nconducted across four clinical sites in the United States. Primary endpoints\nincluded change in peak oxygen uptake (VO2 max) from baseline to Week 24 as\nwell as safety and tolerability. Secondary endpoints included change in\npulmonary vascular resistance (PVR), six-minute walk distance (6MWD) and\nfunctional class assessments. Exploratory endpoints included change in\nN-terminal pro-B-type natriuretic peptide (NT-proBNP) and forced vital\ncapacity (FVC).\n\nWebcast Details\n\n Monday, May 18th @ 10:00 a.m. ET                                                                                                                                                         \n                                                                                                                                                                                          \n Investors:                  1-877-407-0784                                                                                                                                               \n                                                                                                                                                                                          \n International Investors:    1-201-689-8560                                                                                                                                               \n                                                                                                                                                                                          \n Conference ID:              13760654                                                                                                                                                     \n                                                                                                                                                                                          \n Webcast:                    Click Here (https://viavid.webcasts.com/starthere.jsp?ei=1763509&tp_key=187466c723)                                                                          \n                                                                                                                                                                                          \n Call me™:                   Click Here (https://callme.viavid.com/viavid/?callme=true&passcode=13760654&h=true&info=Company-email&r=true&B=6)for instant telephone access to the event.  \n                                                                                                                                                                                          \n\nA replay of the webcast presentation will be temporarily archived on the\nInvestors section of Quince’s website following the presentation.\n\nAbout Quince Therapeutics, Inc.\n\nQuince Therapeutics, Inc. is committed to transforming the lives of patients\nfacing serious, underserved diseases by developing disease-modifying therapies\nto treat their conditions. The company is currently developing LAM-001 for the\ntreatment of pulmonary hypertension associated with interstitial lung disease\n(PH-ILD), bronchiolitis obliterans syndrome (BOS), and sarcoidosis associated\npulmonary hypertension (SAPH).  A Phase 2a study in PH patients has been\ncompleted, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b\nstudy in PH-ILD is anticipated to begin in mid-2026, and a Phase 2 study in\nSAPH is anticipated to begin in late-2026.  By pioneering innovative\napproaches, the company aims to offer new hope and improved quality of life to\npatients worldwide.\n\nForward Looking Statements\n\nStatements in this news release contain “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995 as\ncontained in Section 27A of the Securities Act of 1933, as amended, and\nSection 21E of the Securities Exchange Act of 1934, as amended, which are\nsubject to the “safe harbor” created by those sections. All statements,\nother than statements of historical facts, may be forward-looking statements.\nForward-looking statements contained in this news release may be identified by\nthe use of words such as “believe,” “may,” “should,” “expect,”\n“anticipate,” “plan,” “believe,” “estimated,” “potential,”\n“intend,” “will,” “can,” “seek,” or other similar words.\nExamples of forward-looking statements include, among others, statements\nrelating to the design and potential benefits of LAM-001, including as a\ndisease-modifying therapy for pulmonary disease; anticipated regulatory and\ndevelopment processes and timelines, including the expected timing to initiate\nthe planned Phase 2b trial of LAM-001 in PH-ILD and the planned Phase 2 trial\nof LAM-001 in SAPH, the expected timing for data readouts from the ongoing\nPhase 2 trial of LAM-001 in BOS and the planned Phase 2b trial of LAM-001 in\nPH-ILD; the Phase 2a data of LAM-001 in PAH and PH-ILD supporting continued\ndevelopment of LAM-001 in PH-ILD and the potential benefit across exercise\ncapacity, pulmonary hemodynamics, cardiac stress and lung function; observed\nimprovements in 6MWD and PVR in the Phase 2a trial potentially suggesting\nbroader effects on cardiopulmonary physiology; the estimated patient\npopulations in the U.S. and Europe for PH-ILD, BOS and SAPH; and the potential\nadvantages of mTOR inhibitors in PH-ILD. Forward-looking statements are based\non Quince’s current expectations and are subject to inherent uncertainties,\nrisks, and assumptions that are difficult to predict and could cause actual\nresults to differ materially from what the company expects. Further, certain\nforward-looking statements are based on assumptions as to future events that\nmay not prove to be accurate. Factors that could cause actual results to\ndiffer include, but are not limited to, clinical results may not be indicative\nof results that may be observed in the future, including in larger\npopulations; potential safety and other complications related to LAM-001; the\nability to obtain and maintain regulatory approval; competition in the\ncompany’s industry; the scope, progress and expansion of developing LAM-001;\nthe size and growth of the market(s) therefor and the rate and degree of\nmarket acceptance thereof vis-à-vis alternative therapies; the company’s\nability to attract or retain key management, members of the board of directors\nand other personnel; the impacts of general macroeconomic and geopolitical\nconditions on the company’s business and financial position; and other risks\nand uncertainties described in the section titled “Risk Factors” in the\ncompany’s Annual Report on Form 10-K filed with the Securities and\nExchange Commission (SEC) on April 10, 2026 and other reports as filed with\nthe SEC. Forward-looking statements contained in this news release are made as\nof this date, and Quince undertakes no duty to update such information except\nas required under applicable law.\n\nContacts\n\nCorey Davis, Ph.D.\nLifeSci Advisors, LLC\ncdavis@lifesciadvisors.com  \n212-915-2577\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2d9c6375-d986-407f-affb-1308a5bb5bf6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-18T13:26:19.20435986Z","server_sent_at_ms":1779110779204},"received_at":"2026-05-18T13:26:19.367Z","source_url":null},"analysis":{"id":"27407","press_release_id":"37964","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Small sample size (N=10 total, N=4 PH-ILD subgroup)","Open-label study design lacks placebo control","Phase 2b data not due until Q1 2028, creating a long binary event gap"],"eventType":"clinical_trial","narrative":"Quince Therapeutics reported positive Phase 2a data for LAM-001, an inhaled mTOR inhibitor, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).\n\nThe open-label study showed clinically meaningful improvements in key metrics: 6-minute walk distance increased by 67.4 meters in the PH-ILD subgroup, and pulmonary vascular resistance dropped by 33.9%.\n\nAll evaluable patients improved from Functional Class III to Class II, with two reaching Class I. The company plans to initiate a Phase 2b trial in mid-2026, with topline data expected in Q1 2028.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Strong Phase 2a signals for LAM-001 in PH-ILD drive next-phase development; watch for Phase 2b initiation in H2 2026."},"keyFigures":{"drugName":"LAM-001","phaseOfTrial":"Phase 2a","customDimensions":{"delta_6mwd_meters":81.3,"delta_fvc_percent":4.8,"patients_enrolled":10,"patients_evaluable":6,"phild_subgroup_size":4,"delta_vo2_max_percent":5.4,"delta_ntprobnp_percent":-29,"delta_6mwd_phild_meters":67.4,"delta_pvr_supine_percent":-33.9,"us_patient_population_bos":17000,"delta_pvr_exercise_percent":-25.5,"us_patient_population_saph":60000,"delta_vo2_max_phild_percent":6.7,"us_patient_population_phild":86000,"europe_patient_population_bos":11000,"europe_patient_population_phild":120000}},"quotedText":"What is particularly notable in these early data is the consistency of improvement observed across several important markers of disease burden, including exercise capacity, pulmonary vascular resistance, cardiac stress biomarkers and lung function.","namedEntities":{"people":[{"name":"Aaron B. Waxman","role":"Director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital"},{"name":"Corey Davis","role":"LifeSci Advisors, LLC"}],"products":["LAM-001","rapamycin","sirolimus","treprostinil"],"companies":[{"name":"Quince Therapeutics, Inc.","ticker":"QNCX","relationship":"filer"},{"name":"Orphai Therapeutics, Inc.","relationship":"acquired company"},{"name":"Brigham and Women’s Hospital","relationship":"clinical site"},{"name":"Harvard Medical School","relationship":"academic affiliation"},{"name":"American Thoracic Society","relationship":"conference organizer"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Positive Phase 2a data showing clinically meaningful improvements in key endpoints (6MWD, PVR, NT-proBNP) for lead asset LAM-001 in PH-ILD. The data supports advancement to Phase 2b, de-risking the development path for a rare disease indication with no approved therapies."},"tickerRelevance":{"others":[],"primary":"QNCX"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"positive_clinical_data","sectorWeight":"high","rarity_of_disease":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Quince Therapeutics reported positive Phase 2a data for LAM-001, an inhaled mTOR inhibitor, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).\n\nThe open-label study showed clinically meaningful improvements in key metrics: 6-minute walk distance increased by 67.4 meters in the PH-ILD subgroup, and pulmonary vascular resistance dropped by 33.9%.\n\nAll evaluable patients improved from Functional Class III to Class II, with two reaching Class I. The company plans to initiate a Phase 2b trial in mid-2026, with topline data expected in Q1 2028.","key_figures":{"drugName":"LAM-001","phaseOfTrial":"Phase 2a","customDimensions":{"delta_6mwd_meters":81.3,"delta_fvc_percent":4.8,"patients_enrolled":10,"patients_evaluable":6,"phild_subgroup_size":4,"delta_vo2_max_percent":5.4,"delta_ntprobnp_percent":-29,"delta_6mwd_phild_meters":67.4,"delta_pvr_supine_percent":-33.9,"us_patient_population_bos":17000,"delta_pvr_exercise_percent":-25.5,"us_patient_population_saph":60000,"delta_vo2_max_phild_percent":6.7,"us_patient_population_phild":86000,"europe_patient_population_bos":11000,"europe_patient_population_phild":120000}},"named_entities":{"people":[{"name":"Aaron B. Waxman","role":"Director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital"},{"name":"Corey Davis","role":"LifeSci Advisors, LLC"}],"products":["LAM-001","rapamycin","sirolimus","treprostinil"],"companies":[{"name":"Quince Therapeutics, Inc.","ticker":"QNCX","relationship":"filer"},{"name":"Orphai Therapeutics, Inc.","relationship":"acquired company"},{"name":"Brigham and Women’s Hospital","relationship":"clinical site"},{"name":"Harvard Medical School","relationship":"academic affiliation"},{"name":"American Thoracic Society","relationship":"conference organizer"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-18T13:26:35.760Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"small-cap","eventGravity":"positive_clinical_data","sectorWeight":"high","rarity_of_disease":"high","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":16389,"modelName":"george-droid-qwen-72b"}}